Northland Capmk Increases Earnings Estimates for Indivior

Indivior PLC (NASDAQ:INDV) – Research analysts at Northland Capmk increased their FY2025 earnings per share estimates for shares of Indivior in a research report issued to clients and investors on Thursday, April 24th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of $1.15 per share for the year, up from their previous forecast of $0.90. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

A number of other equities analysts have also commented on the company. Rodman & Renshaw began coverage on Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective on the stock. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Piper Sandler reduced their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th.

Indivior Stock Performance

Indivior stock opened at $11.75 on Monday. The firm has a market cap of $1.62 billion, a P/E ratio of -33.57 and a beta of 0.93. The business’s fifty day moving average is $9.55 and its two-hundred day moving average is $10.38. Indivior has a 52 week low of $7.33 and a 52 week high of $18.59.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.22 by $0.19. The business had revenue of $266.00 million for the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%.

Hedge Funds Weigh In On Indivior

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in shares of Indivior during the fourth quarter valued at $36,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior during the fourth quarter valued at $56,000. Lazard Asset Management LLC acquired a new position in shares of Indivior during the fourth quarter valued at $57,000. Schaper Benz & Wise Investment Counsel Inc. WI acquired a new position in shares of Indivior during the first quarter valued at $95,000. Finally, Cannon Global Investment Management LLC bought a new stake in Indivior in the first quarter valued at about $95,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.